Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: CLTA

Summary for CLTA

Gene information	Gene symbol	CLTA
	Ensembl ID	ENSG00000122705
	Entrez ID	1211
	Gene name	clathrin light chain A
	Synonyms	Lca
	Gene type	protein_coding
	UniProtAcc	P09496

Top

Dataset with differentially expressed gene: CLTA

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	-0.355949	9.81e-45
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	0.457644	8.88e-11
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	0.361891	1.37e-32
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	-0.36109	5.68e-15
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	-0.424782	2.42e-03
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.349485	0.00e+00
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	0.777501	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	0.47816	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	-0.402554	1.99e-09
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.353169	0.00e+00
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	-0.302558	5.41e-27
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	-0.367811	8.69e-23
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	-0.259594	0.00e+00
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	0.710563	0.00e+00
GSE115251	Kelly cell line	Cell line	Neuroblastoma	Neuroblastoma	Targeted therapy	TAE684	NA	Malignant cells	-0.531503	0.00e+00
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	-1.14156	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	-0.867449	0.00e+00

Top

Expression of CLTA in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to CLTA

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating CLTA

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
CLTA	hsa-miR-133a-3p	95.1964	NM_001184761
CLTA	hsa-miR-133b	95.1964	NM_001184761
CLTA	hsa-miR-3159	94.3373	NM_001184762
CLTA	hsa-miR-1252-5p	93.1115	NM_001184762
CLTA	hsa-miR-142-3p	91.3208	NM_001184761
CLTA	hsa-miR-510-3p	90.1067	NM_001184762
CLTA	hsa-miR-4420	89.4347	NM_001184762
CLTA	hsa-miR-181b-3p	89.4347	NM_001184762
CLTA	hsa-miR-181b-2-3p	89.4347	NM_001184762
CLTA	hsa-miR-494-3p	89.3074	NM_001184762
CLTA	hsa-miR-5700	86.9225	NM_001184761
CLTA	hsa-miR-148a-3p	84.9554	NM_001184761
CLTA	hsa-miR-152-3p	84.9554	NM_001184761
CLTA	hsa-miR-148b-3p	84.9554	NM_001184761
CLTA	hsa-miR-6855-5p	83.245	NM_001184761
CLTA	hsa-miR-4510	83.2008	NM_001184761
CLTA	hsa-miR-6129	83.2008	NM_001184761
CLTA	hsa-miR-6133	83.2008	NM_001184761
CLTA	hsa-miR-6130	83.2008	NM_001184761
CLTA	hsa-miR-6127	83.2008	NM_001184761
CLTA	hsa-miR-4744	82.2796	NM_001184762
CLTA	hsa-miR-6878-5p	80.8307	NM_001184761

Page: 1

Top

Motifs and transcription factors (TFs) regulating CLTA

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
CLTA	metacluster_174.3	MBD2; NFYA; NFYB; NFYC; PBX3 (directAnnotation).
CLTA	metacluster_174.2	CEBPZ; CEBPZ; DRAP1; FOS; FOXI1; FOXI1; HMGXB3; IRF3; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYA; NFYB; NFYB; NFYB; NFYB; NFYB; NFYC; NFYC; NFYC; NFYC; NFYC; NFYC; NFYC; PBX3; PBX3; SP2 (directAnnotation). NFYA; NFYA; NFYC; PBX1; PBX3 (inferredBy_Orthology).
CLTA	transfac_pro__M06074	ZNF732 (directAnnotation).
CLTA	hocomoco__TYY2_HUMAN.H11MO.0.D	YY2 (directAnnotation).
CLTA	metacluster_52.11	ZNF184 (directAnnotation).
CLTA	metacluster_174.6	NFYA; NFYB; NFYB; NFYC (directAnnotation).
CLTA	metacluster_191.3	EHF; ELF1; ELF1; ELF1; ELF4; ELK1; ELK3; ELK3; ELK4; ELK4; ERF; ETS1; ETS2; ETV3; ETV4; ETV5; FEV; FEV; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; SPDEF; ZNF200 (directAnnotation). ELK1; ELK1; ELK3; ELK3; ELK4; ELK4; ETV1; ETV1; ETV4; ETV4; ETV4; ETV5; GABPA; GABPA (inferredBy_Orthology).
CLTA	transfac_public__M00024	E2F1 (directAnnotation).
CLTA	swissregulon__mm__E2f7	E2F7 (inferredBy_Orthology).
CLTA	cisbp__M02645	ETS1 (directAnnotation).
CLTA	taipale_tf_pairs__ELF2_NATGCGGAAGTR_HT	ELF2 (directAnnotation).
CLTA	metacluster_138.2	ELF1; ELF2; ELF4; ELK1; ELK1; ELK1; ELK1; ELK3; ELK4; ELK4; ELK4; ELK4; ELK4; ELK4; ELK4; ERF; ERG; ERG; ERG; ERG; ETS1; ETS1; ETS2; ETS2; ETV1; ETV1; ETV1; ETV2; ETV3; ETV4; ETV5; ETV5; FEV; FLI1; FLI1; GABPA; GABPA; KMT2B; SPDEF; SPDEF; SPDEF; ZBTB11; ZNF518A; ZNF580 (directAnnotation). ELF1; ELF2; ELF4; ELK1; ELK1; ELK3; ELK4; ERG; ETS1; ETS2; ETV1; ETV2; ETV3; ETV4; ETV5; FEV; FLI1; FLI1; GABPA; SPDEF; SPDEF (inferredBy_Orthology).
CLTA	jaspar__MA0748.2	YY2 (directAnnotation).
CLTA	metacluster_166.2	ELK4; ETS1; ETS1; ETV1; ETV3; ETV4; ETV5; ETV7 (directAnnotation). GABPA (inferredBy_Orthology).
CLTA	taipale_tf_pairs__ERF_MAX_RSCGGAANCACGTGN_CAP_repr	ERF; MAX (directAnnotation).
CLTA	metacluster_141.4	GLIS2 (directAnnotation).
CLTA	transfac_pro__M06360	ZNF626 (directAnnotation).
CLTA	taipale_tf_pairs__E2F1_ELK1_SGCGCNNNNNNNNNNNCGGAAGN_CAP_repr	E2F1; ELK1 (directAnnotation).
CLTA	swissregulon__hs__ETV6	ETV6 (directAnnotation).
CLTA	taipale_tf_pairs__GCM1_ELK1_RTGCGGGCGGAAGTN_CAP_2	ELK1; GCM1 (directAnnotation).
CLTA	metacluster_161.4	LHX9 (directAnnotation).
CLTA	metacluster_161.3	LHX9 (directAnnotation).
CLTA	taipale_tf_pairs__TFAP2C_ELK1_NGCCTNNGGSNNCGGAAGYN_CAP_repr	ELK1; TFAP2C (directAnnotation).
CLTA	metacluster_141.2	E2F2; E2F3 (directAnnotation).
CLTA	swissregulon__mm__Elf3	ELF3 (inferredBy_Orthology).
CLTA	metacluster_27.11	ZNF140 (directAnnotation).

Page: 1

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."